DR ELLIE CANNON: Cholesterol drug statins and ezetimibe give me tummy ache. Should I stop taking it?
DR ELLIE CANNON: If a medication is doing what it should be but is also causing issues, doctor and patient need to have a serious conversation to weigh up the pros and the cons. (Source: the Mail online | Health)
Source: the Mail online | Health - May 12, 2024 Category: Consumer Health News Source Type: news

FDA Expands Indications for Bempedoic Acid in CVD Prevention FDA Expands Indications for Bempedoic Acid in CVD Prevention
Bempedoic acid and bempedoic –ezetimibe are now indicated to prevent myocardial infarction and cardiovascular procedures in both primary- and secondary-prevention patients regardless of statin use.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 22, 2024 Category: Cardiology Tags: Cardiology Source Type: news

Expanded Label Officially Makes Bempedoic Acid a CVD Prevention Medication
(MedPage Today) -- The FDA approved label expansions for bempedoic acid (Nexletol) and bempedoic acid/ezetimibe (Nexlizet) so they can be used more broadly as cardiovascular prevention drugs, Esperion announced Friday. Based on the CLEAR Outcomes... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - March 22, 2024 Category: American Health Source Type: news

FDA Updates Labels for Two Cholesterol-Lowering Agents FDA Updates Labels for Two Cholesterol-Lowering Agents
New bempedoic acid and bempedoic acid/ezetimibe labels add primary hyperlipidemia and remove the maximally tolerated statin requirement and statement on the effect on mortality.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - December 18, 2023 Category: Cardiology Tags: Cardiology Source Type: news

U.S. FDA Updates LDL-C Lowering Indication for Esperion ’s Nexletol (bempedoic acid) Tablet and Nexlizet (bempedoic acid and ezetimibe) Tablet
Updated Label Adds Primary Hyperlipidemia, Removes Maximally Tolerated Statin Requirement, Removes Limitation of Use Cardiovascular (CV) Risk Reduction Labels Remain on Track: in U.S. with PDUFA Date of March 31; in Europe with Anticipated... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 13, 2023 Category: Drugs & Pharmacology Source Type: news

Upfront Ezetimibe in ACS; New Watchman LAA Occluder OK'd; Low-Cost FH Genotyping
(MedPage Today) -- Compared with statins alone, upfront dual therapy with a statin and ezetimibe (Zetia) was associated with better survival in acute coronary syndrome, a Polish registry showed. (Journal of the American Heart Association) What... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 12, 2023 Category: Cardiology Source Type: news

Combination lipid therapy in acute coronary syndromes 'drastically' cuts risk of death
Patients with acute coronary syndromes (ACS) offered a combination of statins and ezetimibe immediately have a 'drastically reduced' risk of death compared with those starting treatment on statins alone, researchers have said. (Source: GP Online News)
Source: GP Online News - September 5, 2023 Category: Primary Care Tags: Clinical News Source Type: news

Statins Post-PCI: Moderate-Intensity and Add Ezetimibe? Statins Post-PCI: Moderate-Intensity and Add Ezetimibe?
The reward for avoiding high-intensity-statin monotherapy could be better safety and clinical outcomes, suggests a registry study that supports randomized evidence.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - July 25, 2023 Category: Cardiology Tags: Cardiology News Source Type: news

7 Myths About Cholesterol, Debunked
You may not recall every lab value from your last physical, but you probably remember one: Your cholesterol level. If it’s higher than ideal, you’re not alone. According to the U.S. Centers for Disease Control and Prevention, between 2015 and 2018, almost 12% of U.S. adults ages 20 and up had high total cholesterol, defined as above 240 mg/dL. The type that physicians mostly worry about is LDL (or “bad”) cholesterol, which is one component of that total. Why do doctors care so much about cholesterol? First, “it predicts risk,” says Dr. Jeffrey Berger, a cardiologist and director of the C...
Source: TIME: Health - June 19, 2023 Category: Consumer Health News Authors: Katherine Hobson Tags: Uncategorized freelance healthscienceclimate heart health Source Type: news

Liver Fat Lowered by Ezetimibe-Statin Combination Liver Fat Lowered by Ezetimibe-Statin Combination
A significant 5.8% decrease in hepatic steatosis was seen after 24 weeks ’ treatment with ezetimibe and rosuvastatin comparing baseline with end of treatment values.MDedge News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - September 30, 2022 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Ezetimibe Plus Statin: Attractive Bypass to High-Dose Monotherapy Ezetimibe Plus Statin: Attractive Bypass to High-Dose Monotherapy
Early initiation of this approach should be considered in patients with challenging lipid disorders who are at increased risk of atherosclerotic cardiovascular disease events, observers say.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 28, 2022 Category: Consumer Health News Tags: Cardiology News Source Type: news

Panel Addresses Ezetimibe, PCSK9 Inhibitors for Reducing CV Events
THURSDAY, May 5, 2022 -- In a clinical practice guideline published online May 4 in The BMJ, risk-stratified recommendations are presented for whether another lipid-lowering drug should be added among adults with low-density lipoprotein (LDL)... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 5, 2022 Category: Pharmaceuticals Source Type: news

Lipid-Lowering Drug Therapy: A Critical Approach Lipid-Lowering Drug Therapy: A Critical Approach
This review summarizes the main characteristics of statins, ezetimibe, and PCSK9 inhibitors as well as emerging lipid-lowering therapies which will further expand the available armamentarium.American Journal of Cardiovascular Drugs (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 4, 2022 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Kaiser sues big drugmakers around delayed generics for blockbuster cholesterol drugs
The suit centers on Merck's drugs Zetia and Vytorin. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 28, 2021 Category: Biotechnology Authors: Ron Leuty Source Type: news

Kaiser sues big drugmakers around delayed generics for blockbuster cholesterol drugs
The suit centers on Merck's drugs Zetia and Vytorin. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - July 28, 2021 Category: American Health Authors: Ron Leuty Source Type: news